Business Wire

Proximus harnesses ADVA synchronization solution for 5G network timing

23.3.2021 11:00:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that Proximus is leveraging its Oscilloquartz timing technology to synchronize Belgium’s largest open mobile network. The deployment enables Proximus to improve speed, coverage and reliability for millions of mobile users throughout Belgium, while also preparing its network for next-generation services. By deploying ADVA’s core grandmaster devices, access boundary clocks and its enhanced primary reference time clock (ePRTC) solution, the country’s incumbent telecommunications service provider is ensuring the levels of timing accuracy and resilience needed for 5G, broadcast and other time-sensitive services. The technology was implemented by ADVA’s partner Arcadiz Telecom, a leading provider of connectivity solutions across the Benelux region.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005060/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s timing technology is an integral part of Proximus’s 5G strategy (Photo: Business Wire)

“By harnessing ADVA’s network timing innovation, we’re ensuring unprecedented levels of precision and reliability. This deployment is a core component of our 5G strategy. It means more value not only for our customers looking to access data-intensive applications and stream high-quality video wherever they are, but also for telco operators using our open network,” said Patrick Delcoigne, director, network engineering and operations, Proximus. “ADVA’s grandmaster clock and ePRC cesium technology empower us to meet key timing challenges. It enables highly accurate phase precision, enhanced stability and long-term protection from GNSS outages. Just as important, though, is the support of the ADVA and Arcadiz Telecom team. Their engineers have worked closely with us to ensure that the network meets all of our requirements.”

Proximus’s new nationwide synchronization network is built on the OSA 5440, an ultra-stable timing solution optimized for deployment in core networks and the OSA 5412 family of cost-effective, mid-scale synchronization devices engineered for deployment in a wide range of locations. It’s anchored by the robust and proven OSA 3230B ePRC cesium clock installed in two central sites. This supports high levels of frequency stability compliant with the strictest ITU-T standards and, combined with the OSA 5440, ensures long-term stability of UTC time. The extended stability performance of ADVA’s ePRC provides immunity against GNSS outages – a crucial requirement for mission-critical applications that should not rely on satellite-based timing alone.

“For major mobile network operators like Proximus, our PTP grandmaster and boundary clocks and our ePRTC solution are the perfect tools. They enhance overall performance and deliver the precision timing necessary for 5G use cases. Our technology also enables other services such as broadcast networks to migrate to IP-based timing,” commented Jörg Urban, senior director, business development, Oscilloquartz, ADVA. “The OSA 5412 Series and OSA 5440 support a smooth and cost-effective migration to next-generation phase and frequency synchronization. And with our ePRTC solution providing robust backup for GNSS, Proximus’ mobile customers can be sure of high-quality, uninterrupted services with no loss of performance.”

“At Arcadiz Telecom, we know what it takes to build a network ready to support tomorrow’s services. With ADVA’s Oscilloquartz timing technology and the ongoing support and maintenance of our team, Proximus can be confident that its synchronization infrastructure delivers for today’s needs while being fully equipped for the future,” said Marc Vandeputte, CTO, Arcadiz Telecom. “When it comes to 5G connectivity, every nanosecond counts. That’s why the stringent accuracy and stability of ADVA’s technology is so important. It empowers Proximus to deliver enhanced speeds, coverage and quality to its mobile users. For Belgians, this deployment will enable a wide range of new experiences from instant access to video streams to immersive AR and VR experiences.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye